Eiichi Araki

29.6k total citations · 10 hit papers
300 papers, 21.4k citations indexed

About

Eiichi Araki is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Eiichi Araki has authored 300 papers receiving a total of 21.4k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Molecular Biology, 114 papers in Endocrinology, Diabetes and Metabolism and 94 papers in Surgery. Recurrent topics in Eiichi Araki's work include Metabolism, Diabetes, and Cancer (65 papers), Diabetes Treatment and Management (64 papers) and Pancreatic function and diabetes (62 papers). Eiichi Araki is often cited by papers focused on Metabolism, Diabetes, and Cancer (65 papers), Diabetes Treatment and Management (64 papers) and Pancreatic function and diabetes (62 papers). Eiichi Araki collaborates with scholars based in Japan, United States and Australia. Eiichi Araki's co-authors include Masataka Mori, Seiichi Oyadomari, Takeshi Nishikawa, Hiroyuki Motoshima, Motoaki Shichiri, Hideki Kishikawa, Tomomi Gotoh, Shizuo Akira, S. Motoyoshi and Yasuo Ohkubo and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Eiichi Araki

289 papers receiving 20.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1995 2.3k citations Eiichi Araki et al. profile →
Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

2010 1.5k citations Eiichi Araki, Nobuya Inagaki et al. Journal of Diabetes Investigation profile →
Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein

1991 1.3k citations Eiichi Araki et al. profile →
Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene

1994 1.0k citations Eiichi Araki et al. profile →
Targeted disruption of the Chop gene delays endoplasmic reticulum stress–mediated diabetes

2002 760 citations Seiichi Oyadomari, Akio Koizumi et al. Journal of Clinical Investigation profile →
Targeted disruption of the Chop gene delays endoplasmic reticulum stress–mediated diabetes

2002 682 citations Seiichi Oyadomari, Akio Koizumi et al. Journal of Clinical Investigation profile →
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus

2010 520 citations Eiichi Araki, Nobuya Inagaki et al. Diabetology International profile →
Nitric oxide-induced apoptosis in pancreatic β cells is mediated by the endoplasmic reticulum stress pathway

2001 509 citations Seiichi Oyadomari, Kohsuke Takeda et al. profile →
Japanese Clinical Practice Guideline for Diabetes 2019

2020 380 citations Eiichi Araki, Tatsuya Kondo et al. Diabetology International profile →
Japanese Clinical Practice Guideline for Diabetes 2016

2018 268 citations Tatsuya Kondo, Eiichi Araki et al. Diabetology International profile →

Peers

Countries citing papers authored by Eiichi Araki

Since Specialization

Citations

This map shows the geographic impact of Eiichi Araki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiichi Araki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiichi Araki more than expected).

Fields of papers citing papers by Eiichi Araki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiichi Araki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiichi Araki. The network helps show where Eiichi Araki may publish in the future.

Co-authorship network of co-authors of Eiichi Araki

This figure shows the co-authorship network connecting the top 25 collaborators of Eiichi Araki. A scholar is included among the top collaborators of Eiichi Araki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiichi Araki. Eiichi Araki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fingertip skin autofluorescence as a non‐invasive marker for vascular complications in patients with type 2 diabetes 2025 ·Journal of Diabetes Investigation ·(unknown), Takeshi Matsumura, (unknown), Hiroyuki Takahashi, (unknown), (unknown), (unknown), Takahisa Deguchi, Tatsuya Kondo, M. Yamanaka, Ryoji Nagai, Daiji Kawanami, Toshihiko Yanase, Takashi Nomiyama, (unknown), Eiichi Araki, Naoto Kubota	0
2	Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study 2025 ·Journal of Atherosclerosis and Thrombosis ·Hidenori Arai, Shizuya Yamashita, Eiichi Araki, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Daisuke Furukawa, Hideki Suganami, Shun Ishibashi	3
3	Hematopoietic dipeptidyl peptidase-4 deficiency promotes M2 macrophage polarization and attenuates atherosclerosis 2025 ·Biochemical and Biophysical Research Communications ·(unknown), Takeshi Matsumura, (unknown), (unknown), (unknown), (unknown), (unknown), Takafumi Senokuchi, Hiroyuki Motoshima, Tatsuya Kondo, Ryo Hatano, Kei Ohnuma, Chikao Morimoto, Eiichi Araki, Naoto Kubota	0
4	Orally administrated acetate inhibits atherosclerosis progression through AMPK activation via GPR43 in plaque macrophages 2024 ·Atherosclerosis ·Toshiaki Wada, Takafumi Senokuchi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Norio Ishii, Takeshi Matsumura, Yukio Fujiwara, Yoshihiro Komohara, Eiichi Araki, Naoto Kubota	0
5	An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models 2024 ·Diabetologia ·(unknown), (unknown), (unknown), Takuro Watanabe, (unknown), Taha F. S. Ali, (unknown), M. Todaka, Tatsuya Kondo, Mikako Fujita, Masami Otsuka, Eiichi Araki, Hiroshi Tateishi	2
6	Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial 2024 ·Journal of Atherosclerosis and Thrombosis ·Hidenori Arai, Shizuya Yamashita, Eiichi Araki, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, (unknown), Hideki Suganami, Shun Ishibashi	4
7	Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study 2024 ·Journal of Atherosclerosis and Thrombosis ·Shun Ishibashi, Hidenori Arai, Koutaro Yokote, Eiichi Araki, (unknown), (unknown), (unknown), Hideki Suganami, (unknown), Shizuya Yamashita	1
8	Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia—A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study 2024 ·Journal of Atherosclerosis and Thrombosis ·Shizuya Yamashita, Eiichi Araki, Hidenori Arai, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Hideki Suganami, (unknown), Shun Ishibashi	2
9	Causes of death in Japanese patients with diabetes based on the results of survey of 68,555 cases during 2011–2020: committee report on causes of death in diabetes mellitus, Japan Diabetes Society (English version) 2024 ·Diabetology International ·Jiro Nakamura, Narihito Yoshioka, Hideki Katagiri, Kohjiro Ueki, Toshimasa Yamauchi, Nobuya Inagaki, Yukio Tanizawa, Eiichi Araki, Takeo Nakayama, Hideki Kamiya	1
10	LSD1 defines the fiber type-selective responsiveness to environmental stress in skeletal muscle 2023 ·eLife ·Hirotaka Araki, Shinjiro Hino, Kotaro Anan, (unknown), (unknown), Daiki Seko, (unknown), (unknown), Yuko Hino, Yusuke Ono, Eiichi Araki, Mitsuyoshi Nakao	9
11	Significance of Circulating Remnant Lipoprotein Cholesterol Levels Measured by Homogeneous Assay in Patients with Type 2 Diabetes 2023 ·Biomolecules ·(unknown), Takeshi Matsumura, Yuki Kondo, (unknown), (unknown), (unknown), Masahiro Manabe, Tetsumi Irie, Eiichi Araki, Hiroyuki Sugiuchi	1
12	Abstract 13374: Efficacy and Safety of K-877, a Potent and Selective PPAR-α Modulator (SPPARMα), in Combination With Statins in Japanese Patients With Dyslipidemia 2015 ·Circulation ·Hidenori Arai, Shun Ishibashi, Shizuya Yamashita, Eiichi Araki, Koutaro Yokote, Hideki Suganami, Tatsuhiko Kodama	6
13	The serine protease prostasin regulates hepatic insulin sensitivity by modulating TLR4 signalling 2014 ·Nature Communications ·Kohei Uchimura, (unknown), Teruhiko Mizumoto, (unknown), Yutaka Kakizoe, Jun Morinaga, (unknown), (unknown), Miki Ueda, Masataka Adachi, Taku Miyoshi, Naoki Shiraishi, Wataru Ogawa, (unknown), Tatsuya Kondo, Takeshi Matsumura, Eiichi Araki, Kimio Tomita, Kenichiro Kitamura	46
14	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study 2014 ·Cardiovascular Diabetology ·Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto, Kazunori Utsunomiya, Yasuo Terauchi, Kazuyuki Tobe, Yukio Tanizawa, Eiichi Araki, Masamichi Ueda, Hideki Suganami, Daisuke Watanabe, (unknown)	172
15	Abstract 17336: Marked Increase of Plasma Fibroblast Growth Factor 21 in Dyslipidemic Patients Treated With K-877, a Novel Highly Potent and Specific Peroxisome Proliferator-Activated Receptor Alpha Agonist 2013 ·Circulation ·Koutaro Yokote, Shun Ishibashi, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Tatsuhiko Kodama	2
16	Mechanism‐based antioxidant therapies promise to prevent diabetic complications? 2013 ·Journal of Diabetes Investigation ·Takeshi Nishikawa, Eiichi Araki	10
17	Hyperthermia With Mild Electrical Stimulation Protects Pancreatic β-Cells From Cell Stresses and Apoptosis 2012 ·Diabetes ·Tatsuya Kondo, Kazunari Sasaki, (unknown), Saori Morino‐Koga, Hironori Adachi, Mary Ann Suico, Junji Kawashima, Hiroyuki Motoshima, Noboru Furukawa, Hirofumi Kai, Eiichi Araki	37
18	Targeted disruption of the Chop gene delays endoplasmic reticulum stress–mediated diabetes 2002 ·Journal of Clinical Investigation ·Seiichi Oyadomari, Akio Koizumi, Kiyoshi Takeda, Tomomi Gotoh, Shizuo Akira, Eiichi Araki, Masataka Mori	48
19	Targeted disruption of the Chop gene delays endoplasmic reticulum stress–mediated diabetes breakdown → 2002 ·Journal of Clinical Investigation ·Seiichi Oyadomari, Akio Koizumi, Kohsuke Takeda, Tomomi Gotoh, Shizuo Akira, Eiichi Araki, Masataka Mori	760
20	Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts 1998 ·European Journal of Endocrinology ·(unknown), Tetsuya Taguchi, M. Uehara, S. Isami, Hiroki Kishikawa, (unknown), Eiichi Araki, Mototada Shichiri	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact